Clinical Trials for Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder in which a genetic mutation causes red blood cells to be attacked and destroyed by the body's own complement system -- a part of the immune response. This can cause anemia, blood clots, fatigue, and organ damage. Left untreated or undertreated, PNH can be life-threatening.

Treatment with complement inhibitors -- drugs that block the cascade that destroys red blood cells -- has transformed outcomes for people with PNH. But these medications are among the most expensive in the world, and insurance coverage battles are a real and serious problem.

Clinical trials are developing new complement inhibitors and treatment strategies that may offer improved options for people with PNH, including those who have experienced inadequate control on current therapy.

The PNH Alliance and the Aplastic Anemia and MDS International Foundation both maintain resources for people living with PNH.

What Types of Trials Are Available?

Proximal complement inhibitor trials are studying newer agents that block the complement cascade earlier in the pathway, potentially providing more complete control with less breakthrough hemolysis. This is an active and important area of PNH research. Subcutaneous complement inhibitor trials study formulations that can be self-administered at home, rather than requiring intravenous infusions at an infusion center -- a meaningful quality-of-life improvement. Oral complement inhibitor trials study pill-based approaches to PNH treatment, which represent the next horizon in making treatment more accessible. Combination and optimization trials study whether adding a proximal inhibitor to existing C5-directed therapy (like Soliris or Ultomiris) can address residual anemia.

Search ClinicalTrials.gov for currently recruiting PNH trials.

Am I Eligible?

Common eligibility factors for PNH trials include:

- Confirmed PNH diagnosis (detected by flow cytometry with a PNH clone of qualifying size)

- Hemolysis markers (LDH level above a threshold)

- Prior treatment history (some trials enroll treatment-naive participants; others require prior complement inhibitor use)

- No active infections at time of enrollment

- Up-to-date meningococcal vaccination (required for all patients on complement inhibitors, including trial participants)

PNH is a rare disease, and trials are often conducted at specialized hematology centers. Ask your hematologist whether their institution is running any PNH trials or can refer you to a center that is.

Talk to your doctor before making any decisions about your treatment.

What If My Insurance Denied My Medication?

Eculizumab (Soliris) and ravulizumab (Ultomiris) are among the most expensive medications in existence, and insurance denials -- despite their life-sustaining nature for people with significant PNH -- do occur. If your hematologist has prescribed a complement inhibitor and your insurer has denied it, the situation is urgent and worth pursuing aggressively.

Appeal the denial with the strongest possible documentation of your clinical need. Ask your hematologist to escalate with a peer-to-peer review. And simultaneously, explore whether a clinical trial studying a newer complement inhibitor could provide access to treatment.

Ellen can help you figure out your next step. Start with Ellen →

Frequently Asked Questions

Are clinical trials for paroxysmal nocturnal hemoglobinuria free?

In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.

How do I find paroxysmal nocturnal hemoglobinuria trials near me?

The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.

Can I join a trial after being denied Soliris or Ultomiris?

Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Soliris or Ultomiris or similar medications.